**Core Concept:** A drug that binds to a receptor, changing the receptor's affinity for its endogenous ligand, is known as a **allosteric modulator**. These compounds interact with receptors at sites distinct from the active site, influencing the receptor's response without occupying it themselves.

**Why the Correct Answer is Right:** An allosteric modulator (Option C) differs from the other options in its mechanism of action. Unlike competitive antagonists (Option A) that bind to the active site and block the endogenous ligand, or agonists (Option B) that mimic the endogenous ligand and activate the receptor, allosteric modulators bind to a distinct site (allosteric site) on the receptor. This binding changes the receptor's conformation, either enhancing (positive allosteric modulator, Option D) or reducing (negative allosteric modulator, Option C) the receptor's affinity for the endogenous ligand.

**Why Each Wrong Option is Incorrect:**

A. Competitive antagonists (Option A) interact with the active site of the receptor and prevent the endogenous ligand from binding, thus blocking the receptor's response.

B. Agonists (Option B) bind to the receptor's active site and mimic the endogenous ligand, activating the receptor's signal transduction pathways.

**Clinical Pearl:** Understanding the mechanism of action of drugs that target receptors is crucial for deciding the appropriate choice of therapy for various clinical conditions. For example, in the treatment of high blood pressure, you might choose a beta-blocker (e.g., propranolol) as a competitive antagonist at beta-adrenergic receptors, preventing the effects of catecholamines like adrenaline and noradrenaline. Conversely, for asthma treatment, you might opt for a muscarinic antagonist (e.g., atropine) that competes with acetylcholine at muscarinic receptors, blocking their activation.

**Correct Answer:** C. Negative allosteric modulators (Option C) are drugs that bind to a specific site on the receptor and reduce its affinity for the endogenous ligand, thereby decreasing the receptor's response.